Navigation Links
Drug Improves Survival in Mice With Brain Tumors
Date:4/2/2009

Cediranib reduces tissue swelling better than steroids, team says

THURSDAY, April 2 (HealthDay News) -- Anti-angiogenesis drugs reduce edema (swelling of brain tissue) caused by deadly brain tumors called glioblastomas, a new study suggests.

Anti-angiogenesis drugs prevent the formation of new blood vessels that tumors need to grow, the researchers pointed out.

In this study, a Massachusetts General Hospital team found that the experimental anti-angiogenesis drug cediranib reduced edema and improved survival in mice with glioblastomas. The drug inhibits an angiogenesis factor called VEGF, which is abundant in glioblastomas.

"Our findings suggest that anti-angiogenesis therapy can increase patient survival even in the face of persistent tumor growth," study co-senior author Rakesh K. Jain, director of the Steele Laboratory in MGH's radiation oncology department, said in a hospital news release. "In glioblastoma clinical trials, it is important to separate survival analysis from that of tumor response to therapy, since many factors combine to cause patient deaths."

Previous research showed that cediranib temporarily normalized abnormal, leaky blood vessels that had recurred after surgery, radiation or chemotherapy for glioblastoma, reducing edema and the size of tumors. But exactly how the drug did this was unclear. This study clarified that cediranib's beneficial effects resulted from reduction of edema, the study authors said.

"This is the first paper to show that vascular normalization alone, without chemotherapy, can be effective against some tumors by controlling edema, and that this anti-edema effect is better than that of currently used steroids," Jain said.

"Unfortunately, these anti-VEGF agents did not slow the tumor growth rate in these [mouse] models; and since recurrent glioblastomas are highly resistant to currently used chemotherapy drugs, even if vascular normalization increased drug delivery, there may be little or no additional increase in patient survival. We urgently need to find better anti-tumor and anti-angiogenic agents."

The study, which was published online and is expected to be in a future print issue of the Journal of Clinical Oncology, received funding from AstraZeneca Pharmaceuticals, which manufactures cediranib under the brand name Recentin.

More information

The American Brain Tumor Association has more about brain tumors.



-- Robert Preidt



SOURCE: Massachusetts General Hospital, news release, March 30, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
2. Exercise and yoga improves quality of life in women with early-stage breast cancer
3. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
4. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
5. Kerry Extends, Improves Small Business Innovation Program
6. Thalidomide Improves Outcomes for Older Myeloma Patients
7. Grape Consumption Improves Antioxidant Capacity in Humans
8. JCSM: CPAP therapy improves symptoms of depression in OSA patients
9. Early intervention dramatically improves outcomes for new dialysis patients
10. New technique improves purity of medicines
11. Novel medication improves ovarian cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Improves Survival in Mice With Brain Tumors
(Date:4/30/2016)... , ... April 30, 2016 , ... Orlando-based Maximized Living ... they go for gold in Rio. Under the care of Maximized Living doctors ... , In an unprecedented showing, Maximized Living is sending the largest contingent of elite ...
(Date:4/29/2016)... ... April 29, 2016 , ... Since launching its annual volunteer ... serving the footwear industry, has broken all previous participation records in its first ... 23 states during the months of April and May, the 2016 Footwear Cares ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) ... with sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, ... Run and Walk and 1-mile walk were held to increase awareness about Lyme ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... that student team BioCellection won the $30,000 Perlman Grand Prize of the 2016 ... Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee Award for ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... 27, 2016  Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended March 26, ... $0.24 increased 41.2%, and non-GAAP diluted EPS of ... 5.8% on a reported basis, and 6.3% on ... posted another good quarter, highlighted by 14.6% growth ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
Breaking Medicine Technology: